RASAL2 and neoplasm: In keeping with the oncogenic propensity of RASAL2 in TNBC, we previously reported our observation that RASAL2 was overexpressed in the pre-treatment TNBC tumours of patients who had the worst treatment outcome following platinum-based chemotherapy [12, 13].